An Open-label Multi-center Study of Erlotinib (Tarceva) as First Line Therapy Until and Beyond Disease Progression in NSCLC Patients Who Harbour EGFR Mutations.
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ASPIRATION
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 16 May 2017 Status changed from active, no longer recruiting to completed.
- 01 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2017.